Why the study?
Agreement between platelet function tests in clopidogrel-treated patients is only slight to moderate, prompting evaluation of the differential effects of CYP2C19 genotype across tests.
Does CYP2C19 metabolizer status differentially affect on-treatment platelet reactivity as measured by LTA, VerifyNow, and Multiplate in clopidogrel-treated patients post-PCI?
Does CYP2C19 metabolizer status differentially affect on-treatment platelet reactivity as measured by LTA, VerifyNow, and Multiplate in clopidogrel-treated patients post-PCI?
CYP2C19 genotype significantly affects platelet reactivity measured by LTA and VerifyNow, but not Multiplate, partly explaining the disagreement between different platelet function tests.
Answers are grounded in this paper and cite their sources.
May explain inter-assay discordance in clopidogrel response; leaves open optimal platelet testing for genotype-guided therapy post-PCI.
On-treatment platelet reactivity in clopidogrel-treated patients can be measured with several platelet function tests (PFTs). However, the agreement between different PFTs is only slight to moderate. Polymorphisms of the CYP2C19 gene have an impact on the metabolization of clopidogrel and, thereby, have an impact on on-treatment platelet reactivity. The aim of the current study is to evaluate the differential effects of the CYP2C19 genotype on three different PFTs. Methods: From a prospective cohort study, we included patients treated with clopidogrel following percutaneous coronary intervention (PCI). One month after PCI, we simultaneously performed three different PFTs; light transmission aggregometry (LTA), VerifyNow P2Y12, and Multiplate. In whole EDTA blood, genotyping of the CYP2C19 polymorphisms was performed. Results: We included 308 patients treated with clopidogrel in combination with aspirin (69.5%) and/or anticoagulants (33.8%) and, based on CYP2C19 genotyping, classified them as either extensive (36.4%), rapid (34.7%), intermediate (26.0%), or poor metabolizers (2.9%). On-treatment platelet reactivity as measured by LTA and VerifyNow is significantly affected by CYP2C19 metabolizer status (p < 0.01); as metabolizer status changes from rapid, via extensive and intermediate, to poor, the mean platelet reactivity increases accordingly (p < 0.01). On the contrary, for Multiplate, no such ordering of metabolizer groups was found (p = 0.10). Conclusions: For VerifyNow and LTA, the on-treatment platelet reactivity in clopidogrel-treated patients correlates well with the underlying CYP2C19 polymorphism. For Multiplate, no major effect of genetic background could be shown, and effects of other (patient-related) variables prevail. Thus, besides differences in test principles and the influence of patient-related factors, the disagreement between PFTs is partly explained by differential effects of the CYP2C19 genotype.
No takes yet. Share an insight, caveat, or question.
Olie et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: